As a potential treatment of COVID-19: Montelukast

It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.

Detalles Bibliográficos
Autores principales: Fidan, Cihan, Aydoğdu, Ayşe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211747/
https://www.ncbi.nlm.nih.gov/pubmed/32416408
http://dx.doi.org/10.1016/j.mehy.2020.109828
_version_ 1783531508517044224
author Fidan, Cihan
Aydoğdu, Ayşe
author_facet Fidan, Cihan
Aydoğdu, Ayşe
author_sort Fidan, Cihan
collection PubMed
description It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.
format Online
Article
Text
id pubmed-7211747
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72117472020-05-11 As a potential treatment of COVID-19: Montelukast Fidan, Cihan Aydoğdu, Ayşe Med Hypotheses Article It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection. Elsevier Ltd. 2020-09 2020-05-11 /pmc/articles/PMC7211747/ /pubmed/32416408 http://dx.doi.org/10.1016/j.mehy.2020.109828 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Fidan, Cihan
Aydoğdu, Ayşe
As a potential treatment of COVID-19: Montelukast
title As a potential treatment of COVID-19: Montelukast
title_full As a potential treatment of COVID-19: Montelukast
title_fullStr As a potential treatment of COVID-19: Montelukast
title_full_unstemmed As a potential treatment of COVID-19: Montelukast
title_short As a potential treatment of COVID-19: Montelukast
title_sort as a potential treatment of covid-19: montelukast
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211747/
https://www.ncbi.nlm.nih.gov/pubmed/32416408
http://dx.doi.org/10.1016/j.mehy.2020.109828
work_keys_str_mv AT fidancihan asapotentialtreatmentofcovid19montelukast
AT aydogduayse asapotentialtreatmentofcovid19montelukast

Ejemplares similares